Skip to main content

miglustat (Zavesca®)

 

Appraisal in progress

Indication

Status: In progress
 Equality and Health Impact Assessment: miglustat 371 (PDF, 240Kb)
 Evidence Status Report: miglustat 371 (PDF, 133Kb)

Medicine details

Medicine name miglustat (Zavesca®)
Formulation 100 mg capsule
Reference number 371
Indication

For the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease

Company Generic medicine
BNF chapter Nutrition & blood
Submission type Directed
Status In progress
AWMSG meeting date 08/10/2024
Date of issue 20/09/2024
Follow AWTTC: